<DOC>
	<DOCNO>NCT02593682</DOCNO>
	<brief_summary>The purpose study provide information ( pilot data ) whether study drug , suvorexant , ( 1 ) affect level orexin people panic disorder , ( 2 ) associate decreased panic symptom response carbon dioxide ( CO2 ) challenge .</brief_summary>
	<brief_title>The Role Orexin Human Panic Disorder</brief_title>
	<detailed_description>Orexins Hypocretins ( orexins ) , recently identify class pro-arousal neuropeptides , synthesize neuron lateral posterior hypothalamus The main described orexins , orexin A ( ORX A ) orexin B ( ORX B ) , cleave common precursor peptide , prepro-orexin . Orexin A , 33 amino-acid residue peptide , appear conserve across many mammalian specie . Orexin B contain 28 amino acid . Orexins promote variety behavior include alertness , vigilance , locomotion , fight-flight response , feed . The physiological effect orexins mediated via 2 G-protein coupled receptor , ORX1 ORX2 . Orexin A bind great affinity ORX1 receptor , orexin A B bind similar affinity ORX2 receptor . Orexins Animal Fear Models Orexins implicate anxiogenesis animal fear model . For example , central ( icv ) injection orexin A mouse induce anxiety-like response light-dark exploration test elevate plus maze . Using establish , Î³-aminobutyric acid ( GABA ) -deficit , rodent model panic-vulnerability , investigator ' Indiana University preclinical anxiety collaborator provoke panic-like response rodent anxiogenic sodium lactate ( NaLac ) infusion , response blunt follow either site-specific orexin ( ORX ) gene silence systemic pretreatment ORX1 antagonist . In addition , ORX neuron ( peptidergic neuron lateral hypothalamus ) show , turn , stimulate discrete efferent site within emotional network ( e.g. , bed nucleus stria terminalis ) elicit specific behavioral component panic-response follow sodium lactate . Taken together , result support concept ORX hypersecretion ORX neuronal overactivity could also present human panic disorder ( PD ) . Orexins ' Emerging Role Human Anxiogenesis / Panicogenesis Similar NaLac model animal , human PD report cortical subcortical GABA deficit . If GABA deficit also extend impairment GABAergic inhibition dorsomedial hypothalamus ( DMH ) ORX neuron PD patient , predict NaLac animal model , may result ORX hypersecretion , increase sympathetic activation , panicogenesis . There clinical study ORX metabolism function human anxiety population . However , recently generate human pilot data principal investigator 's ( PI 's ) lab , study effect well-documented anxiogenic stimulus ( 35 % CO2 inhalation ) behavioral , physiological , biochemical ( plasma ORX A ; assay standard radioimmunoassays [ RIA ] kit ) measure , 1 PD patient 2 healthy volunteer . In paradigm , PD patient mild panic episode associate mark early elevation plasma ORX level , relative volunteer minimal anxiety , consistent role ORX initiation elaboration human panic response . It also demonstrate , contrast human subject without axis I psychiatric disorder depression alone without panic , subject high panic score depression significantly elevate ORX level cerebrospinal fluid ( CSF ) . The ORX hyperactivity hypothesis panic evince work highly innovative , promise broaden understand neurobiology human panic disorder , well provide new treatment direction . While limitation use plasma ORX A measure central nervous system ( CNS ) ORX function , one research group recently publish human data indicate rest state CSF plasma ORX A level highly correlate . Accordingly , central hypothesis translational human pilot project , definitive project base , follow : PD human anxiety disorder associate specific cortical subcortical GABA deficit result disruption normal inhibitory regulation pro-arousal ORX neuron . This disruption promote excessive ORX release , sympathetic activation , vulnerability spontaneous chemically induced panic . Pretreatment ORX1 receptor antagonist prior chemical challenge therefore expect block evoke panic response . Rationale Use CO2 Inhalation The 35 % CO2 challenge well documented literature reliable , safe , easy administer . The procedure acceptable test-retest reliability , may use monitor improvement clinical status follow administration antipanic medication . Approximately 70 % PD patient panic attack response challenge , closely resemble real-life panic . Therefore , addition resting/baseline measurement plasma ORX A , CO2-evoked level plasma ORX A PD patient also examine , response correlate behavioral physiological parameter record CO2 test . The PI considerable experience use PD challenge paradigm clinical research context , familiar application 35 % CO2 challenge . Project Aims Expected Results The project study gather pilot data relate role orexin human panic disorder . The effect size generate pilot work permit plan power larger-scale study . It anticipate study complete course one year . Specific Aim 1 provide preliminary demonstration acute administration first-in-class , FDA-approved insomnia agent , suvorexant , mixed ORX1/2 receptor antagonist , block 35 % CO2-induced panic symptom PD patient , via amelioration central ORX neuronal hyperactivity ( reflect blunt plasma ORX response CO2 challenge ) . To address Specific Aim 1 , prospective , parallel-group , repeated-measures design use compare behavioral , physiological , biochemical ( plasma ORX ) responses 2 independent , unmedicated group PD outpatient ( n=6 group ) baseline/resting state panic provocation due brief ( 1 minute ) inhalation 35 % CO2 / 65 % O2 gas mixture . PD patient randomize , double-blind manner , receive either single , oral dose mixed ORX1/2 receptor antagonist , suvorexant ( 10 mg dose ) , identical placebo , 120 minute CO2 challenge . Expected result : It expect , compare placebo , suvorexant pretreatment blunt behavioral , physiological , biochemical ( plasma ORX ) responses 35 % CO2 PD , due suppression CNS ORX hyperactivity . The effect size generate pilot work permit plan power larger-scale study , definitively address Specific Aim 1 .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Panic Disorder</mesh_term>
	<mesh_term>Suvorexant</mesh_term>
	<criteria>They must stable physical health determine medical evaluation , include physical examination , electrocardiogram , laboratory finding ( comprehensive metabolic panel , complete blood count [ CBC ] , free T4 , urine pregnancy test , urinalysis ) , urine toxicology screen , negative urine pregnancy test woman childbearing potential . They must satisfy new clinical criterion Diagnostic Statistical Manual Mental Disorders , 5th edition ( DSM5 ) current principal diagnosis PD confirm semistructured , diagnostic interview , Mini International Neuropsychiatric Interview ( MINI ) , administer PI . Since clinical depression ( MDD ) associate CSF ORX abnormality , patient current PD without MDD enrol . They also require current MontgomeryAsberg Depression Rating Scale ( MADRS ) total score &lt; 12 . They regular psychiatric medication avoid drink grapefruit juice least 2 week prior 35 % CO2 test . They must pregnant breastfeed baby ; woman childbearing potential must use birth control study . history psychotic disorder , bipolar disorder , MDD , depression otherwise specify ( NOS ) , obsessive compulsive disorder , eat disorder , posttraumatic stress disorder , generalize anxiety disorder medical condition suvorexant could contraindicate , narcolepsy sleep disorder substance use disorder , define DSM5 , within 6 month screen visit ongoing use psychiatric medication 2 week prior 35 % CO2 test current use certain drug , include strong cytochrome P450 3A ( CYP3A ) inhibitor ( ketoconazole , itraconazole , posaconazole , clarithromycin , nefazodone , ritonavir , saquinavir , nelfinavir , indinavir , boceprevir , telaprevir , telithromycin , conivaptan ) ; moderate CYP3A inhibitor ( amprenavir , aprepitant , atazanavir , ciprofloxacin , diltiazem , erythromycin , fluconazole , fosamprenavir , imatinib , verapamil ) ; strong CYP3A inducer ( rifampin , carbamazepine phenytoin ) ; digoxin history neurological disorder affect CNS history uncontrolled serious medical illness history hypersensitivity allergy suvorexant pregnancy lactation status , unwillingness use birth control study , woman childbearing potential compromise lung function ( e.g. , chronic obstructive pulmonary disease [ COPD ] , emphysema , idiopathic pulmonary fibrosis , lung cancer ) inability fast required amount time prior study visit 2 positive test cannabinoids , opiate , benzodiazepine , amphetamine , cocaine metabolite outofrange lab value abnormal EKG score &gt; 12 MontgomeryAsberg Depression Rating Scale ( MADRS ) inability unwillingness avoid drinking grapefruit juice two week prior 35 % CO2 challenge test history sudden onset muscle weakness ( cataplexy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>